07Jan 2024
Enhanced Efficacy and Safety of Apatinib-Chemotherapy Combo for Metastatic Triple-Negative Breast Cancer in New Study

Enhanced Efficacy and Safety of Apatinib-Chemotherapy Combo for Metastatic Triple-Negative Breast Cancer in New Study

A study assessed the efficacy and safety of low-dose apatinib alongside chemotherapy for metastatic triple-negative breast cancer (TNBC). The study analyzed data from 163 patients and found that the apatinib-chemo combination resulted in superior outcomes (higher ORR, DCR, PFS, and OS) compared to chemotherapy alone. Notably, the apatinib-chemo combo showed lower grade 3/4 non-hematologic toxicities. The findings suggest that this combination is more effective in managing metastatic TNBC with reduced adverse effects compared to chemotherapy alone.

  • #oncology

Like

Save

Share